- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Nirmatrelvir/Ritonavir
- Molnupiravir
Population: Fragile population
Individuals who are more vulnerable to poor health outcomes due to factors like chronic illness, weakened immune systems, disabilities or socioeconomic disadvantages
- Adults
- Elderly
- Fragile population
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Plitidepsin
- Elderly
- Fragile population
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Nirmatrelvir/Ritonavir
- Adults
- Elderly
- Fragile population
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Bamlanivimab/ Etesevimab
- Adults
- Elderly
- Fragile population
- Primary care
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Adults
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
- Adults
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab